Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 4/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.38 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ROS1 | P08922 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22131521 | 0.88 | FABP6 (0.51) | FABP6GSK3BALPLNTRK1JAK2 | |
| SCHEMBL4343282 | 0.77 | ALDH1A1 (0.50) | FABP6ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL13092730 | 0.77 | FABP6 (0.57) | FABP6GSK3BNTRK1JAK2JAK3 | |
| SCHEMBL10274616 | 0.74 | ALDH1A1 (0.56) | FABP6GSK3BALDH1A1GAAHSD17B10 | |
| SCHEMBL14042814 | 0.73 | ALDH1A1 (0.54) | FABP6ALDH1A1GAAHSD17B10MAPT | |
| SCHEMBL12090703 | 0.72 | PARP10 (0.56) | GSK3BKDM4E | |
| SCHEMBL3394900 | 0.72 | ALPL (0.41) | FABP6ALPLNTRK1JAK2HSP90AA1 | |
| SCHEMBL2669099 | 0.72 | ALDH1A1 (0.41) | FABP6GSK3BALPLNTRK1JAK2 | |
| SCHEMBL19984502 | 0.72 | FABP6 (0.48) | FABP6GSK3BALPLNTRK1JAK2 | |
| SCHEMBL30798597 | 0.72 | FABP6 (0.48) | FABP6GSK3BALPLNTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | FABP6 1794/4885GSK3B 2866/4885ALPL 3993/4885 |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | FABP6 1334/4885GSK3B 3517/4885ALPL 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.